Indication: heart failure

Description:

1. For the treatment of acute decompensated heart failure.

2. This product has the same amino acid sequence as the endogenous brain natriuretic peptide produced by ventricular muscle. The prognosis of acute heart failure is very poor. The case fatality rate in hospital is 3%, the rehospitalization rate in 6 months is about 50%, and the case fatality rate in 5 years is as high as 60%.

3. The project was transferred to a domestic pharmaceutical enterprise in 2015 and is carrying out clinical research.